Target intelligence / Profile preview

Reactive oxygen species signaling pathway

Molecular classification
Other (not a receptor, enzyme, transporter, etc.; it is a signaling pathway composed of ROS, antioxidant enzymes, transcription factors, etc.)
01

Overview

The reactive oxygen species (ROS) signaling pathway refers to a network of processes where ROS, particularly superoxide anion and hydrogen peroxide, serve as signaling molecules that regulate diverse physiological and pathological functions. ROS are generated as byproducts of mitochondrial electron transport and by various enzymes, especially NADPH oxidases, under both normal and stress conditions. At physiological levels, ROS act as second messengers to modulate the activity of transcription factors (e.g., NRF2, NF-κB, p53, FoxO), regulate cell proliferation, differentiation, and immune responses, as well as cellular survival and death. Dysregulation of ROS signaling can result in oxidative stress, contributing to a wide range of diseases, including cancer, neurodegenerative disorders, cardiovascular conditions, and chronic inflammation. Therapeutic interventions target components of ROS signaling (such as enhancing antioxidant capacity or inducing ROS-mediated cell death) but targeting the pathway itself is challenging due to the requirement for precise redox balance for normal cellular function

Other names
ROS pathwayReactive oxygen species signalingOxidative signaling pathwayROS signaling
02

Mechanism of action

Antioxidants: Scavenge ROS, reducing signaling and oxidative stress; Pro-oxidants: Increase ROS, enhance cell death in cancer cells; NRF2 activators: Upregulate antioxidant gene expression, restoring redox homeostasis

03

Biological functions

Signal transductionCell cycle regulationApoptosisCell proliferationCell differentiationImmune responseCell deathStress response
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular diseaseDiabetesAgingInfection
05

Safety considerations

Targeting ROS signaling broadly can disrupt normal cellular homeostasisExcessive ROS scavenging may impair physiological signalingInduction of ROS may cause off-target toxicity (e.g., cardiotoxicity with anthracyclines)Balance between pro-survival and pro-death signaling is delicate and context-specific
06

Interacting drugs

Antioxidants (e.g., N-acetylcysteine, vitamin E, vitamin C)

2 more in the full profile.

07

Biomarkers

Intracellular ROS levels (e.g., via DCFDA assay)Expression levels of antioxidant enzymes (SOD, catalase, glutathione peroxidase, NRF2)Redox-sensitive proteins (e.g., glutathionylated proteins)

Beyond the preview

Go deeper on Reactive oxygen species signaling pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reactive oxygen species signaling pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call